Janssen submits NDA to FDA for type 2 diabetes therapy
Linkedin

Janssen submits NDA to FDA for type 2 diabetes therapy

London : United Kingdom | May 31, 2012 at 11:49 PM PDT
Source: Pharmaceutical Industry News
XX XX
Views: Pending
 
The filing is based on a global Phase III clinical development program, including nine multicenter, randomized clinical studies, which evaluated the safety and efficacy of canagliflozin across the spectrum of type 2 diabetes and included placebo- and active comparator-controlled studies. FULL ARTICLE AT Pharmaceutical Industry News
 
  • Clear
  • Share:
  • Share
  • Clear
  • Clear
  • Clear
  • Clear
 
  • Credibility
  • Wait... Flag
 
 
Advertisement
 

More From Allvoices



Use of this site is governed by our Terms of Use Agreement and Privacy Policy.

© Allvoices, Inc. 2008-2014. All rights reserved. Powered by PulsePoint.